paclitaxel/carboplatin(AstraZeneca)은 Neoplasms, Unknown Primary 표적 치료제로, Non-Small-Cell Lung Carcinoma NSCLC 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tisle. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 47% (ClinicalTrials.gov NCT00610714). 차별점: novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R/M-HNSCC.
Neoplasms, Unknown Primary
Non-Small-Cell Lung Carcinoma NSCLC
Recruiting
ADC), was approved by the US Food and Drug Administration for p
representing
linker, and a payload, representing new concept agents without precedence
novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R/M-HNSCC
checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tisle
apoptosis, DNA damage response, and integrin-mediated signaling
PD-1 predominant exposure, tightened outcome definitions, and extended follow
resistance to taxane-based treatments and represents an actionable target for these patients
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
paclitaxel/carboplatin(AstraZeneca)은 Neoplasms, Unknown Primary 표적 치료제로, Non-Small-Cell Lung Carcinoma NSCLC 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tisle. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 47% (ClinicalTrials.gov NCT00610714). 차별점: novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R/M-HNSCC.
Neoplasms, Unknown Primary
Non-Small-Cell Lung Carcinoma NSCLC
Recruiting
ADC), was approved by the US Food and Drug Administration for p
representing
linker, and a payload, representing new concept agents without precedence
novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R/M-HNSCC
checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tisle
apoptosis, DNA damage response, and integrin-mediated signaling
PD-1 predominant exposure, tightened outcome definitions, and extended follow
resistance to taxane-based treatments and represents an actionable target for these patients
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.